(Q37857752)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Managing MS in a changing treatment landscape (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Helene Zephir

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

8

Ralf Gold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Martin Duddy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Aiden Haghikia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Christian Eggers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Jelena Drulovic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Olga Carmona

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

25 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

728-739

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

Defining the clinical course of multiple sclerosis: Results of an international survey

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The immunopathology of multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Interferon-beta mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Concepts of induction and escalation therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Progressive multifocal leukoencephalopathy after natalizumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The human polyomavirus, JCV, uses serotonin receptors to infect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Identification and characterization of mefloquine efficacy against JC virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Development of oral cladribine for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6009-X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Natural history of multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

1 reference

12 December 2020

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

12 December 2020

A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

1 reference

12 December 2020

JCV detection in multiple sclerosis patients treated with natalizumab

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Interferon Beta for Primary Progressive Multiple Sclerosis

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Discrepant findings in immune responses to JC virus in patients receiving natalizumab

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.1007/S00415-011-6009-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21437661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference